Cytochrome P450s (CYPs) comprise a superfamily of enzymes which catalyze the oxidation of a wide variety of xenobiotic chemicals, including drugs and carcinogens.
Multiple-drug therapy is a common therapeutic practice, particularly in patients with several diseases or conditions, and many drug-drug interactions involving metabolic inhibition have been reported. 4, 5) The serotonin-3 (5-HT 3 ) receptor antagonists ramosetron, azasetron, and ondansetron are widely used in the treatment of nausea and emesis induced by cytotoxic chemotherapy and radiotherapy. 6 ) Therefore 5-HT 3 receptor antagonists are coadministered with drugs including anticancer drugs in most cases, and the possibility of interactions between them and other drugs exist. Many anticancer drugs, such as cyclophosphamide, tamoxifen, and paclitaxel, are metabolized by CYPs. 3, 6, 7) However, there are few studies comparing the effect of 5-HT 3 receptor antagonists on human hepatic CYPmediated drug-metabolizing activity under the same experimental conditions.
In the present study, we compared the effects of three 5-HT 3 receptor antagonists on specific activities of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 in human liver microsomes under the same experimental conditions. . S-Mephenytoin, 4Ј-hydroxymephenytoin, oxidized nifedipine, and 6b-hydroxytestosterone were purchased from Ultrafine Chemicals (Manchester, U.K.), and hydroxytolbutamide, 4-hydroxydebrisoquine, and 6-hydroxychlorzoxazone from Sumitomo Chemical Co., Ltd. (Tokyo, Japan). Testosterone, phenobarbital sodium, and p-hydroxybenzoic acid isopropyl were obtained from Nacalai Tesque (Kyoto, Japan), Wako Pure Chemicals (Osaka, Japan), and Tokyo Chemical Industry (Tokyo, Japan), respectively. All other reagents were of the highest purity commercially available.
MATERIALS AND METHODS

Materials
Determination of Human CYP Activities 7-Ethoxyresorufin O-deethylation activity (CYP1A2), tolbutramide hydroxylation activity (CYP2C9), S-mephenytoin 4Ј-hydroxylation activity (CYP2C19), debrisoquine 4-hydroxylation activity (CYP2D6), chlorzoxazone 6-hydroxylation activity (CYP2E1), nifedipine oxidation activity (CYP3A4), and testosterone 6b-hydroxylation activity (CYP3A4) in human liver microsomes in the presence or absence of 5-HT 3 receptor antagonists were determined as described previously. 8, 9) Briefly, the incubation mixture consisted of human microsomes, 2 mM NADP ϩ , 10 mM glucose-6-phosphate, 5 mM magnesium chloride, 1 unit/ml of glucose-6-phosphate dehydrogenase, 100 mM phosphate buffer (pH 7.4), and 5 ml of water or 0.1-4 mM 5-HT 3 receptor antagonists dissolved in water in a final volume of 500 ml. The microsomal protein concentration in the mixture was 0.05 (for nifedipine oxidation), 0.1 (for 7-ethoxyresorufin O-deethylation and testosterone 6b-hydroxylation), 0.2 (for chlorzoxazone 6-hydroxylation), or 0.5 mg/ml (for tolbutamide hydroxylation, Smephenytoin 4Ј-hydroxylation, and debrisoquine 4-hydroxylation). 7, 8) The effects of three serotonin-3 (5-HT 3 ) receptor antagonists, azasetron, ondansetron, and ramosetron, on cytochrome P450 (CYP) 1A2-mediated 7-ethoxyresorufin O-deethylation, CYP2C9-mediated tolbutamide hydroxylation, CYP2C19-mediated S-mephenytoin 4-hydroxylation, CYP2D6-mediated debrisoquine 4-hydroxylation, CYP2E1-mediated chlorzoxazone 6-hydroxylation, CYP3A4-mediated nifedipine oxidation, and CYP3A4-mediated testosterone 6b b-hydroxylation activities in human liver microsomes were compared. Azasetron and ramosetron at a concentration of 1 or 10 m mM neither inhibited nor stimulated any of the metabolic activities. On the other hand, ondansetron competitively inhibited CYP1A2 and CYP2D6 activities, and the inhibition constants (K i ) were 3.2 and 21.0 m mM, respectively, which are much higher than the reported plasma concentrations after clinical intravenous or oral dosing. The free fractions of the three 5-HT 3 receptor antagonists in the incubation mixture estimated by ultracentrifugation were more than 68.6%. These results suggest that azasetron, ondansetron, and ramosetron do not cause clinically significant interactions with other drugs that are metabolized by CYPs via the inhibition of metabolism.
6-hydroxylation, nifedipine oxidation, and testosterone 6b-hydroxylation by human liver microsomes were 0.22, 150.8, 27.3, 83.9, 47.7, 12.2, and 50.3 mM, respectively, 8, 9) concentrations of 7-ethoxyresorufin, tolbutamide, S-mephenytoin, debrisoquine, chlorzoxazone, nifedipine, and testosterone were 0.25, 200, 30, 100, 50, 10, and 50 mM, respectively, which are around the expected K m values. Incubation was carried out at 37°C for 5 min (for testosterone 6b-hydroxylation), 10 min (for 7-ethoxyresorufin O-deethylation, chlorzoxazone 6-hydroxylation, and nifedipine oxidation), 30 min (for tolbutamide hydroxylation and S-mephenytoin 4Ј-hydroxylation), or 60 min (for debrisoquine 4-hydroxylation). 8, 9) In preliminary experiments, the linearity of the reaction with incubation time and protein concentration was confirmed for each assay condition.
Determination of Free Fraction in the Incubation Mixture The incubation mixture consisted of human liver microsomes (0.05-0.5 mg/ml), 1, 10 or 100 mM 5-HT 3 receptor antagonists, and 100 mM phosphate buffer (pH 7.4) in a final volume of 500 ml. After 5-min incubation at 37°C, the mixture was centrifuged at 100000 g for 60 min at 37°C, [10] [11] [12] and the concentration of 5-HT 3 receptor antagonists in the supernatant was measured on HPLC with an analytical column Inertsil ODS-3 (150ϫ4.6 mm i.d., GL Sciences, Tokyo, Japan) equipped with a TSK-guardgel ODS80Ts (3.2ϫ15 mm, Tosoh, Tokyo, Japan). The column temperature was set at 40°C. The elution was conducted with 25% acetonitrile in 20 mM perchlorate buffer (pH 2.5) at a flow rate of 1 ml/min. The elution of the analytes was monitored with UV detection (305 nm for ondansetron and 311 nm for ramosetron), and azasetron was determined fluorometrically (excitation wavelength 318 nm and emission wavelength 380 nm).
Data Analysis All data were analyzed using the average of duplicate or triplicate determinations, and the inhibition constant (K i ) was estimated by fitting the inhibition curves to Eq. 1 or Eq. 2 when the inhibition type was competitive or noncompetitive, respectively:
where v, S, I, V max , and K m are the velocity of the metabolite formation and the concentrations of substrate and inhibitor, the maximum velocity of the metabolite formation, and the apparent Michaelis-Menten constant, respectively. These equations were fitted to data by means of a computer program (MULTI), 13) and fitting evaluation was carried out using Akaike's information criterion.
14) 3 Receptor Antagonists The inhibitory effects of azasetron, ondansetron, and ramosetron at a concentration of 1 or 10 mM on metabolic activities in human liver microsomes are shown in Fig. 1 . The three 5-HT 3 receptor antagonists neither inhibited nor stimulated any of the metabolic activities except that ondansetron at a concentration of 10 mM inhibited CYP1A2 and CYP2D6 activities by 44% and 23%, respectively. Therefore the effects of ondansetron on CYP1A2 and CYP2D6 activities were investigated in detail (Fig. 2) . Ondansetron competitively inhibited CYP1A2-mediated 7-ethoxyresorufin Odeethylation and CYP2D6-mediated debrisoquine 4-hydroxylation, with K i values of 3.2 and 21.0 mM, respectively. Free Fraction in the Incubation Mixture The free fractions of 5-HT 3 receptor antagonists in the incubation mixture (0.05-0.5 mg protein/ml) were determined at 1, 10, and 100 (ondansetron) mM after ultracentrifugation ( Table 1) . The free fractions of azasetron, ondansetron, and ramosetron were 81.4-96.7%, 79.7-98.5%, and 68.6-92.1%, respectively. Although a minor decrease in free fraction at the higher protein concentration was observed for ondansetron and ramosetron, the independence of compound concentration was shown for the three 5-HT 3 receptor antagonists as well as many other drugs including imipramine, propranolol, troglitazone, and amitriptyline. [15] [16] [17] [18] 
RESULTS
Inhibition of CYP Activities by 5-HT
DISCUSSION
After oral or intravenous administration in humans, 48-67% of azasetron is excreted as an unchanged drug in urine, [19] [20] [21] [22] and there are few reports on the metabolic enzymes of azasetron. On the other hand, the metabolism of ondansetron is catalyzed by multiple CYP isoforms, including the CYP1A2, CYP2D6, and CYP3A subfamily, 23) and ramosetron is metabolized by CYP1A1/2 and CYP2D6 (Astellas Pharma Inc., unpublished results). In this study, we found that azasetron, ondansetron, and ramosetron at a concentration of 1 or 10 mM neither inhibited nor stimulated any of the metabolic activities except that ondansetron competitively inhibited CYP1A2 and CYP2D6 activities with K i values of 3.2 and 21.0 mM, respectively (Figs. 1, 2) . In addition, the free fractions of three 5-HT 3 receptor antagonists in the incubation mixture estimated by ultracentrifugation were more than 68.6% ( Table 1 ), suggesting that the protein binding in the incubation mixture is of minor importance. The maximum plasma concentrations (C max ) after intravenous or oral dosing of azasetron, ondansetron, and ramosetron are September 2006 September 1933 Table 2 . [19] [20] [21] [24] [25] [26] [27] [28] The clinical therapeutic doses of azasetron and ondansetron in Japan are 10 mg and 4 mg, respectively, for both intravenous and oral dosing, and those of ramosetron for intravenous and oral dosing are 0.3 mg and 0.1 mg, respectively. Therefore the clinical C max values of azasetron, ondansetron, and ramosetron after intravenous dosing, which were estimated by dose normalization of the reported C max in Table 2 , are around 0.5 mM, 0.2-0.3 mM, and 0.04 mM, respectively, and 0.07-0.10 mM, 0.04-0.05 mM, and 0.001 mM, respectively, after oral dosing. No inhibition by azasetron and ramosetron at 10 mM concentration, which is 20-and 250-fold, respectively, higher than the expected C max after intravenous dosing, was observed. Additionally, the K i values of ondansetron against CYP1A2 and CYP2D6 activities were 10-16-and 70-100-fold higher than the C max value of ondansetron after intravenous dosing.
The concentrations of azasetron, ondansetron, and ramosetron in the incubation mixture (10 mM) were 100-140-, 200-250-, and 10000-fold, respectively, higher than the expected C max values after clinical oral dosing. When the substrate concentration is much lower than the K m value, the ratio of intrinsic metabolic clearance (CL int ) in the presence and absence of the inhibitor can be expressed by the following equation, independent of the inhibition type, except in the case of uncompetitive inhibition, 29, 30) 
where I u is the unbound concentration of the inhibitor. Additionally, when the absorption rate is maximum, the maximum inflow blood concentration of the inhibitor into liver (I in,max ) after oral dosing can be expressed as
where I p,max , R B , k a , D, Q H , and F a represent the maximum plasma concentration of the inhibitor in the circulation, blood-to-plasma concentration ratio, absorption rate constant, dose, hepatic blood flow, and the fraction absorbed from the gastrointestinal tract into the portal vein, respectively. After oral dosing(s) of 10 mg azasetron, 4 mg ondansetron, or 0.1 mg ramosetron, the peak plasma concentrations (I p,max ) are expected to be 26-33 ng/ml (0.07-0.09 mM), 11-20 ng/ml (0.04-0.07 mM), or 0.34-0.47 ng/ml (0.001-0.002 mM), respectively. 20, 21, [25] [26] [27] Free fractions of I in,max (I in,u,max ) for azasetron, ondansetron, and ramosetron after oral dosing are calculated using the free fraction in plasma ( f u ) ϭ 0.688, 0.12, and 0.09, respectively, with R B ϭ1 (R B was assumed to be 1 because R B has not been reported.), k a ϭ0.1 min
Ϫ1
, Q H ϭ1610 ml/min, F a ϭ1 to avoid false-negative predictions, to be 1.2 mM, 0.10-0.11 mM, and 0.002 mM, respectively. In this paper, we demonstrated that the inhibition of human CYPs by azasetron and ramosetron was not observed at 10 mM (Table 1) , which is 8-5000-fold higher than the predicted I in,u,max . In addition, the 1ϩI in,u,max / K i values of ondansetron for CYP1A2 and CYP2D6 were 1.03 and 1.005, respectively. Based on these estimations, as well as on the lack of inhibition of CYPs by azasetron and ramosetron, it is speculated that the three 5-HT 3 receptor antagonists after intravenous or oral dosing would not cause clinically significant interactions with other drugs metabolized by CYPs via the inhibition of metabolism. There are no clinical reports that azasetron, ondansetron, and ramosetron increase the blood concentrations of other CYP-metabolized drugs as a result of inhibition of their metabolism.
Ondansetron competitively inhibited CYP1A2 and CYP2D6 activities with K i values of 3.2 and 21.0 mM, respectively. In addition, it appears that ondansetron inhibits the 4-hydroxylation of cyclophosphamide, an anticancer drug, with an IC 50 value of Ͼ100 mM.
31) Cyclophosphamide 4-hydroxylation is catalyzed by multiple CYP isoforms, with CYP2B6 displaying the highest activity, 31) and multiple CYP forms, including the CYP1A2, CYP2D6, and CYP3A subfamily, are involved in the metabolism of ondansetron in humans. 23) On the other hand, Gilbert et al. 32) reported that a 17% increase in the clearance of cyclophosphamide was observed in the presence of continuous-infusion ondansetron during highdose chemotherapy for breast cancer, suggesting the possibility of CYP induction. 6) In conclusion, the present study suggests that azasetron, ondansetron, and ramosetron do not cause clinically significant interactions with other drugs that are metabolized by CYPs, such as CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4, via the inhibition of metabolism.
